|
Multiple Myeloma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We revealed that the expression of FAM46C, which has been reported as a tumor suppressor for multiple myeloma, was enhanced after NCTD treatment.
|
28341836 |
2017 |
|
Multiple Myeloma
|
0.060 |
Biomarker
|
disease |
BEFREE |
FAM46C is known as a tumor suppressor in multiple myeloma.
|
30573978 |
2018 |
|
Multiple Myeloma
|
0.060 |
Biomarker
|
disease |
BEFREE |
All four human FAM46 paralogs (FAM46A, FAM46B, FAM46C, FAM46D) are thought to be involved in several diseases, with FAM46C reported as a causal driver of multiple myeloma; however, their exact functions remain unknown.
|
27060136 |
2016 |
|
Multiple Myeloma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Together these results implicate FAM46C in myeloma cell growth and survival and identify <i>FAM46C</i> mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis.<i></i>.
|
28619709 |
2017 |
|
Multiple Myeloma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
|
21994415 |
2011 |
|
Multiple Myeloma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Here the authors show that FAM46C is a poly(A) polymerase and that loss of function of FAM46C drives multiple myeloma through the destabilisation of ER response transcripts.
|
28931820 |
2017 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We revealed that the expression of FAM46C, which has been reported as a tumor suppressor for multiple myeloma, was enhanced after NCTD treatment.
|
28341836 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Together, these data show that FAM46C shows tumor suppressor properties and such effects are mediated, at least in part, by Wnt/b-catenin in GC.
|
31585903 |
2020 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Low FAM46C expression levels were significantly associated with larger macroscopic GC tumor sizes.
|
27770343 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Overall, our data suggest that FAM46C probably acts as a tumor suppressor gene in OSCC cells and the working mechanism of FAM46C may be involved in the caspases and ERK1/2 pathway.
|
30573978 |
2018 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Gene set enrichment analysis on The Cancer Genome Atlas liver HCC (LIHC) dataset revealed that metastasis down pathway was strongly associated with FAM46C expression.
|
28123642 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Together these results implicate FAM46C in myeloma cell growth and survival and identify <i>FAM46C</i> mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis.<i>Cancer Res; 77(16); 4317-27.©2017 AACR</i>.
|
28619709 |
2017 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, these data show that FAM46C shows tumor suppressor properties and such effects are mediated, at least in part, by Wnt/b-catenin in GC.
|
31585903 |
2020 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Copy number alterations were found in six GC cell lines with differing FAM46C transcription levels.
|
27770343 |
2017 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, these data show that FAM46C shows tumor suppressor properties and such effects are mediated, at least in part, by Wnt/b-catenin in GC.
|
31585903 |
2020 |
|
Stomach Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Copy number alterations were found in six GC cell lines with differing FAM46C transcription levels.
|
27770343 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Gene set enrichment analysis on The Cancer Genome Atlas liver HCC (LIHC) dataset revealed that metastasis down pathway was strongly associated with FAM46C expression.
|
28123642 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Together these results implicate FAM46C in myeloma cell growth and survival and identify <i>FAM46C</i> mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis.<i>Cancer Res; 77(16); 4317-27.©2017 AACR</i>.
|
28619709 |
2017 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Author Correction: FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells.
|
29230037 |
2017 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of FAM46C in two HCC cell lines, SMCC-7721 and SK-Hep-1, significantly repressed cell proliferation, and increased cells population in G2/M phase and cell apoptotic rate.
|
28341836 |
2017 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The potential functions of FAM46C in oral squamous cell carcinoma.
|
30573978 |
2018 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Gene set enrichment analysis on The Cancer Genome Atlas liver HCC (LIHC) dataset revealed that metastasis down pathway was strongly associated with FAM46C expression.
|
28123642 |
2017 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, negative correlation between Toll-like receptor 4 (TLR4) and FAM46C in sepsis was observed.
|
30910647 |
2019 |
|
Malignant neoplasm of mouth
|
0.010 |
AlteredExpression
|
group |
BEFREE |
However, there are few studies about the expression and function of FAM46C in oral squamous cell carcinoma (OSCC), which is one of the most common oral cancers in the world.
|
30573978 |
2018 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, negative correlation between Toll-like receptor 4 (TLR4) and FAM46C in sepsis was observed.
|
30910647 |
2019 |